Phoenix Molecular Designs (PhoenixMD), a Vancouver, Canada-headquartered biopharmaceutical company designing cancer therapeutics, has partnered with STA Pharmaceutical, a WuXi AppTec company, to manufacture PMD-026, a first-in-class, specific ribosomal S6 kinase inhibitor, needed for investigational new drug (IND)-enabling toxicology studies and a Phase I study in women for treating breast cancer.

Under the agreement, STA will become a new manufacturing partner for PhoenixMD for its platform of kinase inhibitor drug candidates to treat a range of unmet medical needs, with an initial focus on triple negative breast cancer. STA will be responsible for the early manufacturing work through their GMP-certified site in San Diego, California. Through these collaborative efforts, PhoenixMD expects to file an IND application for PMD-026 with the US Food and Drug Administration.

Source: Phoenix Molecular Designs